deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT02979691

Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01

A Phase II/III Study Comparing Simultaneous Integrated Boost (SIB) Intensity Modulated Radiation Therapy (IMRT) With S1 Based SIB-IMRT Followed by Adjuvant Chemotherapy With S1 in Elderly Patients With Esophageal or Esophagogastric Cancer (3JECROG-P01)

Sponsor: Affiliated Hospital of Hebei University

Conditions Chemoradiation Esophagogastric Junction Cancer Esophagus Cancer Radiotherapy; Complications
Interventions S-1 SIB-IMRT
Updated 13 times since 2017 Last updated: Jul 18, 2020 Started: Oct 31, 2016 Primary completion: Apr 30, 2020 Completion: Apr 30, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Chemoradiation and Esophagogastric Junction Cancer, this trial is completed. The trial is conducted by Affiliated Hospital of Hebei University and has accumulated 13 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Oct 2017 · 9 months · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Oct 2019 · 13 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Aug 2020 · 9 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Oct 2023 · 10 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  4. Dec 2022 — Oct 2023 [monthly]

    Completed PHASE2_PHASE3

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE2_PHASE3

▶ Show 8 earlier versions

  1. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

    Status: Recruiting → Completed

  2. Nov 2019 — Aug 2020 [monthly]

    Recruiting PHASE2_PHASE3

  3. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE2_PHASE3

  4. Sep 2018 — Oct 2019 [monthly]

    Recruiting PHASE2_PHASE3

  5. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE2_PHASE3

  6. Nov 2017 — Jun 2018 [monthly]

    Recruiting PHASE2_PHASE3

  7. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE2_PHASE3

  8. Jan 2017 — Oct 2017 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Affiliated Hospital of Hebei University
  • Anyang Tumor Hospital
  • Chinese Academy of Medical Sciences
  • Fujian Cancer Hospital
  • Hebei Medical University Fourth Hospital
  • Sichuan Cancer Hospital and Research Institute
  • Tengzhou Central People's Hospital
  • The Affiliated Hospital of Inner Mongolia Medical University
  • The First Affiliated Hospital of Zhengzhou University
  • The First Affiliated Hospital with Nanjing Medical University
  • Tianjin Medical University Cancer Institute and Hospital
Data source: ChineseAMS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations